electroCore Third Quarter 2026 Earnings Call - ELECTROCORE INC

Financial Performance:

• Reported record net sales of $9.7 million for Q3 2026, representing a 12% year-over-year increase.
• Achieved the lowest operating loss in company history: a loss of $1.6 million, with a net loss of $1.3 million ($0.13 per share), a significant improvement from $3.1 million ($0.33 per share) in Q2 2026.
• Adjusted EBITDA loss narrowed to $700,000 (a $1.4 million or 67% improvement year-over-year), approaching break-even faster than previously projected.
• Gross margin expanded to 88.5% from 86% in the prior year period, driven by favorable product mix and the acquisition of Quell Fibromyalgia.
• Cash, cash equivalents, and marketable securities totaled $7.5 million as of September 30, 2026; inventory increased to $4 million to support anticipated prescription business growth.
• Total operating expenses were $10.1 million, essentially flat year-over-year but down from $10.1 million in Q2 2026; SG&A remained stable while R&D expenses decreased to $400,000.

Guidance and Future Outlook:

• Revised full-year 2026 revenue guidance to $39–42 million (previously >30% growth), citing a delay in the acceleration of sales organization changes to 2027.
• Provided preliminary 2027 guidance of 30–40% year-over-year revenue growth, contingent on successful execution of the new sales model.
• Projects achieving the first quarter of positive adjusted EBITDA by the end of 2027 using current cash reserves and existing financing, without requiring dilutive equity.
• Anticipates the FDA response for the CIPN 510K submission in the second half of Q1 2027, with potential revenue contributions from this indication expected in the back half of 2027.

Business Segments and Product Lines:

• Quell Fibromyalgia: October 2026 marked the company's best month for Quell, with patient count exceeding 1,000 in 2026; national refill rate is currently 42% with a goal to reach 70% through improved patient training.
• Prescription GammaCore: Sales driven by VA channel growth; 91% of VA orders in September processed through Lovell Government Services, a key distributor partner.
• TrueVega (DTC): Deliberately reduced DTC revenue to prioritize profitability over top-line growth; return on advertising spend (ROAS) improved 8% year-over-year.
• New Indications: Filed FDA 510K pre-market notification in late October for Quell to treat chemotherapy-induced peripheral neuropathy (CIPN).
• Emerging Markets: Engaged with Kaiser (CA), Department of Defense/TRICARE, VA Women's Health, and First Responders; identified pilot areas for federal workers' compensation.

Market and Competitive Landscape:

• CIPN represents a "blue ocean" market with an estimated US TAM of $600–700 million, currently lacking specific pharmaceutical or medical device approvals.
• VA market penetration improved: top 15 accounts contributed 51% of VA revenue (down from 54%), indicating reduced concentration risk; top 30 accounts dropped from 73% to 71%.
• Competitors bidding on TrueVega branded search terms increased 60%, necessitating a strategic pivot to efficient, profitable growth in the DTC channel.
• New market entry strategies focus on leveraging partnerships with federal consultants and national opinion leaders to drive adoption.

Risks and Challenges:

• Regulatory Timing: FDA review timelines for the 510K submission and the historical open Form 483 (related to legacy OTC products) remain uncertainties, though management does not expect the Form 483 to delay the CIPN review.
• Sales Execution: The ramp-up of the new sales force and territory realignment is taking longer than planned, delaying the anticipated acceleration in the second half of 2026.
• Capital Management: While currently self-funding, the company is evaluating refinancing options for its existing term loan to extend principal repayment timing, though no agreements are finalized.
• Customer Concentration: Continued reliance on the VA and Department of Defense channels poses concentration risks, necessitating diversification into commercial markets.

Management Commentary and Tone:

• Management expressed high confidence ("conviction and excitement") regarding the company's trajectory, describing the quarter as the strongest in company history for financial metrics.
• Tone emphasized a strategic pivot from "chasing empty calorie revenue" to building durable, profitable, and repeatable revenue streams.
• CEO Josh Lev and COO Mike Fox highlighted a "discipline-first" approach, noting that sales organization changes are proving effective with new reps generating 30% more revenue than previous holders of the same territories.
• Chairman Dr. Thomas Errico framed the quarter as foundational, positioning the company for an inflection point toward positive adjusted EBITDA in 2026 and accelerated growth in 2027.

Analyst Questions and Answers:

• Sales Force Capacity: Management indicated no immediate saturation risks in VA markets; target goal is approximately 14 new patients per month per account, combining migraine and fibromyalgia indications.
• CIPN Commercialization: While the core sales force may suffice, management acknowledged potential future need for specialized oncology-focused resources if CIPN clearance is granted.
• DTC Strategy: TrueVega revenue is expected to grow year-over-year but at a significantly slower pace to ensure profitability; management refuses to chase unprofitable growth.
• Regulatory Pathway: Confirmed the switch from De Novo to 510K for CIPN was driven by the FDA team's assessment that a predicate device exists, which management views as a positive signal.
• Addressable Market: CIPN TAM estimated at $600–700 million in the US, with a specific VA addressable market of $15–20 million; plans to expand beyond federal space post-clearance.
• Over-the-Counter Quell: Launch of an OTC Quell product is delayed pending resolution of regulatory feedback on previous OTC models, aligning with the current focus on profitable revenue.

Other Key Points:

• Operational Shifts: Transitioned VA sales to 91% via Lovell Government Services in September, expected to reduce transaction fees by 3% and free internal resources for new market expansion.
• Sales Efficiency: New independent representatives onboarded since June averaged $210,000/month in VA revenue in Q3, trending toward $300,000/month, compared to $160,000 previously; new patient starts reached 3.4 per account in the third month, up from 0.3 historically.
• Refill Rate Strategy: Piloting new patient training initiatives to improve compliance and refill rates, with expected improvements visible in Q4 2026 and continuing into 2027.
• Strategic Focus: Emphasis on "three imperatives" for growth: expanded VA coverage, smaller territories with clear accountability, and proven new sales methodologies.